^
Association details:
| Biomarker: | FLT3-ITD mutation + FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TRIPLE COMBINATION OF HMA, VENETOCLAX, AND FLT3 INHIBITOR PRODUCES HIGHER FLT3 PCR CLEARANCE, FLOW MRD NEGATIVITY, AND IMPROVED MEDIAN OS COMPARED WITH DOUBLETS OF HMA WITH FLT3 INHIBITOR
Published date:
05/12/2021
Excerpt:
We identified 77 adult pts with newly diagnosed FLT3m (ITD and/or TKD) AML who were treated with LIC including first-generation (sorafenib, midostaurin) LIC doublet (n=44), second-generation (quizartinib) LIC doublet (n=16), and HMA-VEN-FLT3i (sorafenib, gilteritinib, midostaurin) triplet (n=17)....With a median follow-up of 28 months, pts treated with triplets achieved the best median OS compared with pts treated with first- or second-generation FLT3i based LIC doublets (not reached vs 15.7 vs 8.7 months (m), respectively, p=0.01).
